Image Extension
- Desktop
- Tablet
- Mobile
Image Extension
- Desktop
- Tablet
- Mobile
VENCLYXTO® offers patients with CLL a chance to
BREAK FREE with longer progression-free survival1*†
Headline & Text
VENCLYXTO® offers patients with CLL a chance to
BREAK FREE with longer progression‑free survival1*†
NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab
NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab
In 2L+ CLL:
VENCLYXTO + rituximab
*Reduced risk of progression or death vs O+Clb (HR=0.35; 95% CI: 0.23–0.53 [P<0.0001]). Median follow‑up of 28 months. Median PFS not reached in either arm.
†Reduced risk of progression or death vs BR (HR=0.17; 95% CI: 0.11–0.25 [P<0.0001]). Median follow‑up of 23.8 months. Median PFS not reached with VEN+R vs 17 months (15.5–21.6) with BR.
VENCLYXTO® OFFERS PATIENTS WITH CLL A CHANCE TO
BREAK FREE with longer progression-free survival
VENCLYXTO in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).
VENCLYXTO in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
[Placeholder for safety statement, per local regulations]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
*Reduced risk of progression or death vs O+Clb (HR=0.35; 95% CI: 0.23–0.53 [P<0.0001]) Median follow-up of 28 months. Median PFS not reached in either arm.
†Reduced risk of progression or death vs BR (HR=0.17; 95% CI: 0.11–0.25 [P<0.0001]). Median follow-up of 23.8 months. Median PFS not reached with VEN+R vs 17 months (15.5–21.6) with BR.
VENCLYXTO-based regimens now proven in two phase 3 clinical trials, opening treatment possibilities for more patients with CLL
*Treatment complete after twelve 28-day cycles.1
†Treatment complete after 5-week dose-titration period and twenty-four 28-day cycles.1
‡Secondary endpoint. Deep response as indicated by CR or MRD negativity.
§Sustained off-treatment response based on 2-year (CLL14) and 4-year (MURANO) updated efficacy analyses.1,3
CLL=chronic lymphocytic leukemia; 1L=first line; O+Clb=obinutuzumab + chlorambucil; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO + rituximab; VEN+O=VENCLYXTO + obinutuzumab; 2L+=second line + later lines of therapy; CR=complete remission; CRi=complete remission with incomplete marrow recovery; INV=investigator; MRD=minimal residual disease; PB=peripheral blood; ITT=intent to treat; 1° EP=primary endpoint; NR=not reached; OS=overall survival; AR=adverse reaction; TLS=tumor lysis syndrome.
I want to find out
more
about VENCLYXTO
I want to receive more information
about VENCLYXTO
References: 1. VENCLYXTO Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG. 2. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236. 3. Seymour JF, Kipps TJ, Eichhorst B, et al. Time-limited venetoclaxrituximab in relapsed/refractory chronic lymphocytic leukaemia: first presentation of 4-year data from the MURANO study. Presented at: XVIII International Workshop on CLL (iwCLL); September 20-23, 2019; Edinburgh, Scotland. Poster #2266.